DeloRes trial: study protocol for a randomized trial comparing two standardized surgical approaches in rectal prolapse - Delorme’s procedure versus resection rectopexy

Simone Rothenhoefer1, Florian Herrle1†, Alexander Herold2, Andreas Joos2, Dieter Bussen2, Meinhard Kieser3, Petra Schiller3, Christina Klose3, Christoph M Seiler4, Peter Kienle1 and Stefan Post1*

Abstract

Background: More than 100 surgical approaches to treat rectal prolapse have been described. These can be done through the perineum or transabdominally. Delorme’s procedure is the most frequently used perineal, resection rectopexy the most commonly used abdominal procedure. Recurrences seem more common after perineal compared to abdominal techniques, but the latter may carry a higher risk of peri- and postoperative morbidity and mortality.

Methods/Design: DeloRes is a randomized, controlled, observer-blinded multicenter trial with two parallel groups. Patients with a full-thickness rectal prolapse (third degree prolapse), considered eligible for both operative methods are included. The primary outcome is time to recurrence of full-thickness rectal prolapse during the 24 months following primary surgery. Secondary endpoints are time to and incidence of recurrence of full-thickness rectal prolapse during the 5-year follow-up, duration of surgery, morbidity, hospital stay, quality of life, constipation, and fecal incontinence. A meta-analysis was done on the basis of the available data on recurrence rates from 17 publications comprising 1,140 patients. Based on the results of a meta-analysis it is assumed that the recurrence rate after 2 years is 20% for Delorme’s procedure and 5% for resection rectopexy. Considering a rate of lost to follow-up without recurrence of 30% a total of 130 patients (2 x 65 patients) was calculated as an adequate sample size to assure a power of 80% for the confirmatory analysis.

Discussion: The DeloRes Trial will clarify which procedure results in a smaller recurrence rate but also give information on how morbidity and functional results compare.

Trial registration: German Clinical Trial Number DRKS00000482

Keywords: Rectal prolapse, Surgery, Delorme’s procedure, Resection rectopexy, Recurrence
recurrence of full-thickness rectal prolapse. For many patients, constipation and fecal incontinence improve after surgery [4,7,8].

Basically, two different surgical approaches can be distinguished: perineal and transabdominal procedures. In general, perineal surgical repairs supposedly cause less morbidity and mortality compared with abdominal operations [7,9,10]. They are considered especially indicated in the elderly and/or high-risk patients as they can also be done in spinal or epidural anesthesia [9,11,12]. On the other hand, recurrences seem more frequent after perineal techniques than after abdominal operations [1-3,13]. Abdominal repairs involve fixing the rectum to the sacrum by using either mesh or sutures. In addition to rectopexy a sigmoid resection is commonly performed. Laparoscopic repair of rectal prolapse has similar morbidity and recurrence rates as open surgery [7,14]. There are data suggesting that the laparoscopic compared to the conventional approach has short-term benefits as described for other laparoscopic abdominal procedures (reduced length of hospital stay, less postoperative pain, faster return to normal bowel function, and less wound complications) [9,15]. But when using a modern fast-track regime (involving multimodal balanced anesthesia and analgesia including peridural catheter, early normal nutrition and mobilization as well as avoidance of tubes and catheters) the advantages of a laparoscopic approach have become somewhat less clear [15-17]. In general the fast-track regime allows enhanced recovery and discharge of patients compared to conventional postoperative management. Application of such a fast-track regime allows compensation of assumed disadvantages like more pain or slower mobilization of patients after open abdominal surgery compared to laparoscopic surgery.

In conclusion, perineal as well as abdominal (mostly laparoscopic) procedures remain the established options in the surgical treatment of rectal prolapse without evidence from adequately designed randomized studies which of these procedures are superior. There are only insufficient data available on the long-term benefits and risks, quality of life, and total treatment costs. Our trial aims to contribute to the very scarce high-level-evidence basis of randomized trials comparing a perineal vs. an abdominal approach. The urgent need for a randomized trial such as DeloRes was also pointed out in the Cochrane Review by Tou in 2009 [18].

Methods/Design

Trial design

DeloRes is a randomized, controlled, observer-blinded multicenter trial with two parallel groups.

Patient population

**Inclusion criteria**

- Full-thickness rectal prolapse, externally visible on straining
- ASA-Score I-III
- Patient is suited for both standardized surgical approaches
- Patient is able to cooperate
- Patient has given written informed consent
- Aged 18 years or older

**Exclusion criteria**

- Recurrence of full-thickness rectal prolapse
- Patient with stoma
- Patient with inflammatory bowel disease
- Pregnancy or breastfeeding
- Patient currently under chemotherapy
- Active malignant disease and life expectancy less than 24 months
- Body mass index greater than 40
- Participation in another intervention trial with interference of intervention and outcome of this study

The aim was to exclude as few patients as possible, but nevertheless minimize attrition bias in long-term follow-up and enable a high recruitment rate given the fact that patients presenting with full rectal prolapse are a small population of a reasonably higher population of patients not willing to present at their physicians because of misinformation or shame.

Thus patients with recurrent rectal prolapse would often not be acceptable for surgeons to be randomized to perineal vs. abdominal approach especially if the prior surgery had been a perineal approach. Patients not surviving at least 24 months would not be available for the primary endpoint visit at 24 months postoperatively. And patients with BMI > 40 had been excluded as they are very few and do not represent the common patient habitus of rectal prolapse.

Scheme of intervention

DeloRes will be performed in 13 trial centers. All participating centers are cooperating units with a special focus on colorectal surgery and all centers perform between eight and sixty surgical interventions for rectal prolapse per year. In order to minimize performance bias, only surgeons with an adequate experience in performing the approaches investigated operate on patients in this study (minimum number of procedures performed ‘life-time experience’): Delorme’s procedure=20, (laparoscopic) resection rectopexy=20). Each study center provides at
least one surgeon with the required experience for Delorme’s procedure and one surgeon with the required experience for (laparoscopic) resection rectopexy (expertise based, best team approach). To ensure standardization for all participating centers an operative manual with standardized video sequences will be prepared. Moreover, consented crucial steps of each procedure will be captured in the clinical record file. In addition, in order to allow confirmation of a certain procedure quality, selected digital photos will be taken.

To reflect current practice and to increase external validity of the trial, perioperative standards (for example, bowel preparation, parenteral nutrition, fast-track, postoperative application of laxatives) will not be strictly standardized. Each trial center, however, will document its own standards in a short questionnaire and agrees not to change this standard during trial recruitment.

Recruitment and trial timeline
Recruitment of participants started in September 2010. The duration of the trial for each patient is expected to be 60 months with follow-up at 6, 12, 24, and 60 months after the primary surgery.

Treatment assignment and randomization
Consecutively screened and eligible patients will be included in the trial. In order to achieve comparable intervention groups, patients will be allocated by preoperative randomization 24 to 48 h prior to surgery after given written informed consent using a centralized web based tool (www.randomizer.at). Block randomization stratified by center will be applied to achieve equal group sizes per center.

Interventions and trial flow
The laparoscopic approach is considered the standard approach for the transabdominal operation of full-thickness rectal prolapse. Laparoscopic resection rectopexy is suggested to yield better results in the early postoperative phase in comparison to the open approaches with equal recurrence rates in comparison to the open approach. However, the advantages of a laparoscopic approach become somewhat less evident under a fast-track regime, therefore open resection rectopexy is also acceptable via a Pfannenstiel incision. The latter approach has proven to be only moderately invasive in numerous procedures of the lower abdomen. The most frequently used perineal procedure is Delorme’s procedure, which shows low postoperative morbidity. The trial flow is illustrated in Figure 1.

Description of trial days
All patients will be informed about the purpose of the trial and surgical treatment modalities comprising their benefits as well as risks. The schedule of trial interventions is presented in Table 1.

Outcome measures and definitions
The clinically most relevant parameter in the treatment of full-thickness rectal prolapse is the time to recurrence. Therefore this parameter is defined as primary outcome measure, evaluated during the 24 months following primary surgery. Recurrence is defined as the circular protrusion of rectal mucosa through the anal canal and will be examined by standardized history, clinical examination, and photo documentation. To assess the primary outcome, patients are asked to perform a straining maneuver in a sitting position (patients not able to sit will be assessed in a lateral decubitus position). Then a photograph is taken during straining. The primary outcome is finally determined by the independent review board on the basis of the photograph.

Secondary endpoints are time to and incidence of recurrence of full-thickness rectal prolapse during 5-year follow-up, duration of surgical intervention, morbidity, SAE, all causes of mortality within 3 months after primary surgery (this period was chosen to get any mortality possible related to surgery. Patients with rectal prolapse are usually rather old and frail. There are multiple reasons for further morbidity or mortality which are expected to be unrelated to the surgical procedure in case they occur beyond the first 3 months), length of initial hospital stay, reoperation rate for recurrent prolapse, cumulative hospital stay and change in quality of life, constipation, and fecal incontinence as measured by appropriate questionnaires.

The time to and the incidence of recurrence of full-thickness rectal prolapse during a 5-year follow-up after primary surgery will be assessed as explained above. Morbidity occurring during the primary hospital stay is further differentiated into surgical and non-surgical complications, which are specifically defined as following: severity grading is done with the Clavien classification [19] and for anastomotic leakage with the classification of the International Study Group of Rectal Cancer [20]. The definitions of the secondary outcomes are shown in Table 2.

Data management
All protocol-required information collected during the trial must be documented in the paper-based CRF by the investigator. Any outstanding entries must be completed immediately after the final examination. The completed CRF must be reviewed and signed by the investigator named in the trial protocol.

In order to ensure that the database reproduces the CRFs correctly a double entry of data will be performed by two different people.
Figure 1 Trial flow/intervention scheme.

Screening of patients with full rectal prolapse (n = 350)
- n = 35 (10%) fulfilling exclusion criteria
- n = 35 (10%) no compliance
- n = 150 (40%) no informed consent

Compliant patients fulfilling inclusion criteria with informed consent (n = 130)

Randomization 24 to 48 hours prior to surgery

Delorme's procedure (n = 65)
- Discharge day
- Recurrence until 6 months
- Recurrence until 12 months
- Recurrence until 24 months
- Recurrence until 60 months
- To be analyzed n = 65

Resection rectopexy (n = 65)
- Discharge day
- Recurrence until 6 months
- Recurrence until 12 months
- Recurrence until 24 months
- Recurrence until 60 months
- To be analyzed n = 65

Expected drop-outs in each group (n = 15)*
Compliance/rate of loss to follow-up
To reduce the number of patients not able or willing to visit the study centers a study nurse will be appointed to visit the patients and to assess the outcome at the specified time (‘flying study-nurse’). Furthermore, the time-to-event method will be applied for the primary analysis to allow for all available information including the observation time of patients who drop out early. Nevertheless, an additional percentage of patients will be recruited to assure a sufficient power for the confirmatory analysis.

Safety assessments and reporting of adverse events
Analysis of safety-related data is performed with respect to frequency of serious adverse events, frequency of serious adverse events stratified by intensity and causality, and frequency of morbidity in both treatment groups.

From the day of randomization until the regular end of trial follow-up or until premature withdrawal of the patient, all serious adverse events must be documented on a ‘serious adverse event form’ available in the investigator site file.

A serious adverse event will be defined as an event that results in death, is immediately life-threatening, requires or prolongs hospitalization beyond the 20th postoperative day for any medical reason, requires readmission for any medical reason within 3 months after the operation within this trial, requires readmission for treatment of surgical complications related to the study operation beyond 3 months postoperatively, or results in persistent or significant disability or incapacity. Serious adverse events will be classified in intensity (mild, moderate, severe), outcome (recovered completely, recovered with sequelae, not recovered, death, unknown), and causality (unrelated, possibly related, probably related, definitely related, not assessable).

The assessment is based on surgical findings and the clinical course of the patient. It needs to be done by the investigators. Serious adverse events have to be reported by the attending physician to the coordinating investigator or one of both study supervisors within 24 h after the SAE becomes known.

Statistical methods
Sample size calculation
The sample size calculation is based on the analysis of the primary endpoint (time to recurrence of full-thickness rectal prolapse during a 2-year follow-up). A meta-analysis including 17 publications (Delorme [2,5,6,8,9,12,13,25]; (Laparoscopic) Resection Rectopexy [1,3,4,7,14,26-28]) showed recurrence rates ranging from 10% to 30% (Delorme’s procedure) and from 0% to 11% (laparoscopic resection rectopexy) (Table 3). Based on these data, we assume a recurrence rate 2 years after randomization of 20% for the Delorme’s procedure and 5% for resection rectopexy, respectively. If the unstratified two-sided log rank test at level of significance \( \alpha = 5\% \) was applied 2 x 50 = 100 patients would be required to achieve a power of 1 - \( \beta = 80\% \) (nQueryAdvisorR 7.0, [29]). It is expected that the rate of loss to follow-up without recurrence of full-thickness rectal prolapse will add up to 30%. Even though the lack of information on the primary endpoint at 2 years for these patients is partly addressed by the applied time-to-event method, another 30% of patients will be randomized to compensate for this partial loss of information. It can be expected that application of the center-stratified version
of the log rank test will further increase the power. Based on these considerations, a total of 130 patients (2 x 65 patients) will be allocated to the trial which should be sufficient to assure a power of 80% for the confirmatory analysis.

**Analysis**

The allocation of all patients to the different analysis populations will be defined prior to the analysis (full analysis set (FAS) according to the intention-to-treat principle (ITT; all randomized patients as randomized), per protocol (PP) analysis set, safety analysis set). The procedure of allocation will be documented in the statistical analysis plan. During the data review, deviations from the protocol will be assessed as ‘minor’ or ‘major’. Major deviations from the protocol will lead to the exclusion of a patient from the PP analysis set.

The confirmatory analysis is performed for the full analysis set. The null-hypothesis ‘no difference in the time to recurrence of full-thickness rectal prolapse between experimental and control intervention during the 2-year follow-up after randomization’ is tested by

---

**Table 2 Definitions of secondary outcomes**

| Surgical complications | Postoperative ileus | Obstructive or paralytic symptoms after surgery with the need to suspend food intake and/or insert a gastric tube; this has to be confirmed radiologically (by abdominal sonography or plain abdominal X-ray or CT scan) |
|-------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Postoperative hemorrhage| Need for administration of two or more red cell concentrates within the first 24 h postoperatively or need for reoperation |
| Surgical site infection | CDC definition (21) |
| Intra-abdominal abscess  | Intra-abdominal collection of purulent or infected fluid (confirmed by culture) confirmed by puncture or by surgical reintervention |
| Anastomotic leakage     | Grade A-C, Definition of grade according to International Study Group of Rectal Cancer 2010, diagnosed by CT scan with radiographic enema, endoscopy, drain secretion (stool) or reoperation |

**Non-surgical complications**

- **Thrombosis**: Clinical evidence (for example, pain, swelling, warmth, erythema) of a leg or pelvic vein thrombosis confirmed by duplex sonography or CT angiography, which was not previously known
- **Pulmonary embolism**: Clinical (for example, tachycardia, dyspnea) and/or radiological evidence of pulmonary embolism confirmed by spiral CT or lung perfusion scintigram
- **Postoperative pulmonary infection**: At least three of the following:
  - temperature > 38°C
  - purulent tracheal secretion
  - leucocytes >12 or < 4.5 [10E9/L]
  - elevated CRP
  - AND Evidence for pulmonary infection radiologically
- **Renal failure**: Need for dialysis or hemofiltration
- **Cerebral insult**: Ischemic or non-ischemic cerebrovascular event with persistent paresis or paralysis without previous history confirmed by CT or MRT
- **Myocardial infarction**: Electrocardiogram (NSTE or STEMI) and enzyme (Troponin I) changes suggestive of myocardial infarction or needing admission to coronary care unit

**Serious adverse events**

- **SAE occurring from the day of randomization until regular end of trial follow-up or withdrawal**
- **Mortality**: All causes of mortality within 3 months after primary surgery
- **Duration of surgical intervention**: First incision to the completion of skin closure (resection rectopexy) or the last coloanal suture (Delorme’s procedure)
- **Length of initial hospital stay**: Means the hospitalization period from the primary operation date until the day of discharge (= postoperative hospital stay)
- **Reoperation rate for recurrent prolapse**: Any surgical intervention for a recurrence
- **Cumulative hospital stay**: Defined by the days in hospital after the primary surgery as well as the following hospitalizations due to complications or recurrence within 24 months after the primary operation
- **Change of quality of life, constipation and incontinence**: Measured by means of the appropriate questionnaires SF-12, (22), validated in German), Herold constipation score (23), evaluated in German, but not yet published), Wexner-Score (10), non-validated in German, most commonly used score) and Rockwood-FIQLScore (24), validated), prior to the surgical intervention as well as 6, 12, and 24 months after the intervention
application of the log rank test stratified by center at the
two-sided level $\alpha=5\%$. Drop-out and lost-to-follow-up
without recurrence of full-thickness rectal prolapse are
considered as censoring events.

For the analysis of the secondary outcomes descriptive
methods will be used, including the calculation of appro-
priate summary methods for the empirical distribution as
well as calculation of descriptive two-sided $P$
values for
comparisons of treatment groups. A special focus of the
exploratory analyses will be on the time course of the pri-
mary as well as the secondary endpoints. Additionally, sen-
sitivity analyses will be conducted for different study
populations (per protocol population, appropriate sub-
groups). Further exploratory analyses will be performed to
develop potential prognostic factors for the intervention ef-
fect. The time to recurrence of full-thickness rectal
prolapse will additionally be analyzed applying a Cox
regression model that includes covariates of potential prog-
nostic value.

The safety analysis is based on all randomized patients
who were treated with the interventions under investiga-
tion. The analysis includes calculation and comparison of
the rates of specified complications (see secondary
endpoints) and serious adverse events as well as of se-
verity and relationship to intervention and graphical
display of the time course. Furthermore, statistical meth-
ods are used to assess the quality of data and the homo-
geney of intervention groups.

All analyses will be done using SAS version 9.1 or
higher.

Withdrawals
Participants are allowed to withdraw their written
informed consent for the trial at any time and without giv-
ing reasons for their decision. If investigators or members
of the independent Data Monitoring and Safety Board raise
any concerns on an individual patient’s safety, the patient
will be withdrawn from the trial.

Stopping guidelines
The surgical interventions applied in this trial are clinic-
ally established standard methods for the treatment of
rectal prolapse. Therefore, SAEs that will cause a prema-
ture end of the trial are not anticipated.

The DSMB will be informed about the recruitment
and relevant safety data in regular time intervals. If any
safety concerns arise, the DSMB members will confer on
the continuation of the trial and can recommend stop-
ning of the trial. The Ethic Committees then have to be
informed.
Trial organization and administration

Funding
DeloRes is funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).

Monitoring
Clinical monitoring will be performed by an institution which is independent from other trial staff and experienced due to participation in many other surgical trials. Monitoring procedures will be adapted to the study specific risks for the patients and standard operating procedures (SOP) will be implemented to ensure patients safety and integrity of the clinical data, for example, primary endpoint in adherence to study protocol. Pre-study visits will be performed in centers interested in participating in the study in order to ensure high compliance quality of the participating centers concerning, for example, patient recruitment and documentation. Prior to study start, all participating centers will be personally trained and introduced into all study specific procedures during individual on site initiation visits. Regular on-site monitoring visits are planned at all sites depending on the recruitment rate and quality of the data (approximately one visit per site and year). The investigator must allow the monitor to look at all essential documents and must provide support at all times to the monitor. For all subjects clinical source data verification (SDV) for all clinical items is planned. The extent of further SDV and/or the frequency of monitoring visits will be adapted for individual centers in case of bad quality of data or if common protocol violations are observed. In return, frequency of monitoring visits can be reduced for reliable and compliant centers with high data quality. In addition to the SOPs all procedures will be pre-defined in a study-specific monitoring manual. Queries (for example, in case of missing values, implausibility, etc) have to be answered by the investigators in a timely manner in order to avoid that errors in data capture or entry are held on to.

Data and safety monitoring board (DSMB)
To enable an independent risk assessment for the different surgical procedures, potentially related serious adverse events will be noted and periodically assessed by the independent Data and Safety Monitoring Board (DSMB). Detailed working procedures are defined in a different document.

Steering committee
An independent steering committee will be established. The steering committee will supervise the conduct of the trial and will issue recommendations for early termination, modifications or continuation of the trial, if necessary. The steering committee must be informed in a timely manner of SAE.

Ethical and legal aspects
Before the start of the trial, the trial protocol, informed consent document, and any other trial documents were submitted to the independent ethics committee.

The realization of this trial is ethically justifiable since both surgical techniques are routinely used. Study-specific medical interventions exceeding this routine are not planned. Regarding the benefit/risk ratio of this trial for patients, no ethical objections for the realization should exist.

The procedures set out in the trial protocol, pertaining to the conduct, evaluation, and documentation of this trial, are designed to ensure that all persons involved in the trial abide by Good Clinical Practice (GCP) and the ethical principles described in the current revision of the Declaration of Helsinki. The trial will be carried out in keeping with local legal and regulatory requirements.

Benefit-risk assessment
Benefit-risk assessment will be critically reviewed and has to be approved by the ethics committees in advance before first recruitment.

All interventions applied in this trial represent clinically established, standard methods of treating full-thickness rectal prolapse. Therefore the applicants do not anticipate any serious adverse event that might be triggered due to the patient’s participation in the trial itself.

Discussion
An evidence-based optimal surgical treatment for all patients with rectal prolapse does not exist [30]. Currently, there is no valid evidence as no conclusive data are yet available from larger randomized or even adequately case-controlled studies. Perineal approaches, such as the Delorme’s procedure, are deemed less invasive compared to abdominal procedures. Further advantages are shorter intervention time and the possibility to perform the operation under spinal or epidural anesthesia. On the other hand, the recurrence rates after such an approach are thought to be significantly higher than after an abdominal approach.

A prospectively randomized, adequately powered trial comparing these two established operation techniques with prolapse recurrence as primary outcome has never been successfully completed. In addition, trial registers of ongoing prospective studies do not indicate that there currently is a recruiting trial investigating this question (last search October 7, 2011).

An updated Cochrane review of Tou et al. [18] could only include one RCT comparing a perineal to an abdominal approach in a single center setting with a sample size of 20 and a median follow-up period of 17 months. In this study only one recurrence occurred in the perineal group.
[31]. An urgent need for high quality randomized clinical trials with adequate statistical power, long-term follow-up, and quality of life assessment is concluded by the authors and reference is made to the PROSPER Trial still ongoing at the time of the Cochrane review update.

The so-called PROSPER Trial in the United Kingdom [32] compared abdominal to perineal surgical approaches for rectal prolapse in a pragmatic two-stage randomization trial design depending on the surgeons degree of uncertainty which of four approaches to choose. The study was able to recruit 293 patients from 33 centers over a 7-year period from February 2001 up to the cessation of the trial in August 2008, but only 26 patients were actually randomized to one of the two approaches (last available newsletter from December 2005, see trial website). All other patients were allocated to one of the two procedures by surgeon’s preference. In view of the very small number of patients actually randomized to a perineal versus an abdominal approach, the conclusions of this study are going to be very limited and the risk of selection bias is high. In addition, the majority of recruiting centers recruited less than 10 patients to the study, further reducing the validity of the results.

Considering the lessons learned from the PROSPER Trial, an urgent need currently exists for an adequately powered, simple parallel-group randomized trial comparing the abdominal to the perineal approach in rectal prolapse. Contrarily to the PROSPER Trial, clinical equipoise regarding the two surgical approaches has been concluded after extensive discussion of the available data as the confidence intervals of the published studies on the two approaches overlap considerably. Even if the study shows that the abdominal procedure results in significantly less recurrences this may be outweighed by a considerably higher morbidity and possibly less improved quality of life. This trial therefore only allows randomization to a perineal or abdominal approach. A loss of eligible patients to an observational non-randomized arm, as was the case for the majority of patients in the PROSPER Trial, will not be possible.

This trial is designed as an expertise-based trial aiming at strong internal validity by high performance and standardization. Generalizability may be reduced by the expertise-based trial design. However, this type of surgery in larger numbers is predominantly performed by specialized surgeons. For these surgeons but also for general surgeons operating only on a few cases per year the results of this trial should have an important impact on clinical practice by determining the most effective treatment for rectal prolapse.

In summary, considering the scarce high-level evidence available up to date we hope that our trial will add the necessary and confirmatory data to analyze which surgical approach is indeed superior.
9. Oliver GC, Vachon D, Eisenstat TE, Rubin RJ, Salvati EP. Delorme’s procedure for complete rectal prolapse in severely debilitated patients. An analysis of 41 cases. Dis Colon Rectum 1994, 37:461–467.

10. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum 1993, 36:77–97.

11. Tobin SA, Scott IH. Delorme operation for rectal prolapse. Br J Surg 1994, 81:1681–1684.

12. Watkins BP, Landercasper J, Beizer GE, Rechner P, Knudson R, Bintz M, Lambert P. Long-term follow-up of the modified Delorme procedure for rectal prolapse. Arch Surg 2003, 138:498–502.

13. Pescatori M, Intersiano A, Stolfi VM, Zoffoli M. Delorme’s operation and sphinctero-plasty for rectal prolapse and fecal incontinence. Int J Colorectal Dis 1998, 13:223–227.

14. Stevenson AR, Sitz RW, Lumley JW. Laparoscopic-assisted resection-recto-pexy for rectal prolapse: early and medium follow-up. Dis Colon Rectum 1998, 41:46–54.

15. Kulny E, Schwenk W, Gaupit R, Romild U, Bonjer J. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treat Rev 2008, 34:498–504.

16. Sajid M, Siddiqui M, Baig M. Open vs laparoscopic repair of full-thickness rectal prolapse: a re-meta-analysis. Colorectal Dis 2009, 13:1552S.

17. Sammour T, Kahokehr A, Srinivasa S, Bissett IP, Hill AG. Laparoscopic colorectal surgery is associated with a higher intraoperative complication rate than open surgery. Ann Surg 2011, 253:33–43.

18. Tou S, Brown SR, Malik AI, Nelson RL. Surgery for complete rectal prolapse in adults. Cochrane Database Syst Rev 2008, BCD001758.

19. Dindo D, Demartines N, Clavien PA. Classification of Surgical complications: A new Proposal with evaluation in a cohort of 6336 Patients and results of a survey. Ann Surg 2004, 240:205–213.

20. Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, Holm T, Wong WD, Tiett E, Moriya Y, Laurberg S, den Dulk M, van de Velde C, Büchler MW. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 2010, 147:339–351.

21. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992, 13:606–608.

22. Ware J Jr, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220–233.

23. Braun M, Herald A, Krammer H, Schlieger F. Evaluierung eines Scores zur Unterscheidung verschiedener Obstipationsformen. Coloproctology 2006, 28.

24. Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thomson AG, Wexner SD, Bliss D, Lowry AC. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index. Dis Colon Rectum 1999, 42:1525–1532.

25. Senapati A, Nicholls RJ, Thomson JP, Phillips RK. Results of Delorme’s procedure for rectal prolapse. Dis Colon Rectum 1994, 37:456–460.

26. Kim DS, Tsang CB, Wong WD, Lowry AC, Goldberg SM, Madoff RD. Coloproctology: evolution of management and results. Dis Colon Rectum 1999, 42:460–466.

27. Carpelan-Holmström M, Krauwe O, Scheinin T. Laparoscopic rectal prolapse surgery combined with short hospital stay is safe in elderly and debilitated patients. Surg Endosc 2006, 20:1353–1359.

28. Huber FT, Stein H, Stiewert JR. Functional results after treatment of rectal prolapse with resection and sigmoid resection. World J Surg 1995, 19:138–143.

29. nQuery Advisor® Release 7.0. Statistical Solutions: Saugus, MA. www.statistical-solutions-software.com/products-page/nquery-advisor-sample-size-software.

30. Schiedel TH, Schwander O, Scheele J, Farke S, Bruch HP. Rectal prolapse: which surgical option is appropriate? Langenbecks Arch Surg 2005, 390B–1–4.

31. Deen R, Grant E, Billingham C, Kegley MRF: Abdominal resection recto-pexy with pelvic floor repair versus perianal rectosigmoidectomy and pelvic floor repair for full-thickness rectal prolapse. Br J Surg 1994, 81:302–304.

32. PROSPER – PROlapse Surgery FInal or Recto-pexy: http://www.prosper.bham.ac.uk.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit